



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Zang et al.

§ ART UNIT:
§ 1644

FILED: July 2, 2003

§ EXAMINER:
§ Juedes, A.E.

SERIAL NO.: 10/612,468

§ DOCKET:
§ D6622

FOR: T Cell Receptor CDR3 Sequence
and Methods for Detecting and
Treating Rheumatoid Arthritis

MAIL STOP SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ATTN: Examiner Amy E. Juedes

COMPLIANCE OF REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Dear Sir:

Applicant hereby provides a computer readable form of the Sequence Listing on the enclosed diskette and a paper copy thereof for the above-referenced application. The disk is IBM formatted and was made using Windows XP. The file is stored as D6622SEQ in text format. I hereby state that the content of the paper copy of the Sequence Listing filed as part of the above-referenced application and the enclosed computer readable copy of the Sequence Listing are the same, and no new matter has been introduced.

Respectfully submitted,



Benjamin Aaron Adler, Ph.D., J.D.
Counsel for Applicant
Registration No. 35,423

Date: Dec 3, 2008
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
Tel.: (713) 270-5391
Fax: (713) 270-5361
Ben@adlerandassociates.com